VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

Vascular Biogenics Ltd. (NASDAQ:VBLT) began the Phase III OVAL trial of ofranergene obadenovec (VB-111) to treat recurrent platinum-resistant ovarian cancer.

The U.S. and Israeli trial will evaluate ofranergene obadenovec plus chemotherapy vs. chemotherapy alone in up to 350 patients. The primary endpoint is overall survival (OS). Secondary endpoints include objective response rate (ORR), progression-free survival (PFS), combined CA-125 and RECIST 1.1 response (GCIG criteria) and patient reported outcome measures. Gynecologic Oncology Group (GOG) Foundation Inc. (Philadelphia, Pa.) will conduct the trial...